Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan. We show 16 historical shares outstanding datapoints in our DCTH shares outstanding history coverage, used to compute DCTH market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing DCTH market cap history over the course of time is important for investors
interested in comparing DCTH's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of DCTH versus a peer is one thing; comparing
DCTH market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like DCTH can fluctuate over the course of history.
With this page we aim to empower investors researching DCTH by allowing them to research the DCTH market cap history. |
Free DCTH Email Alerts:
Video: The Importance of Market Cap
